Cipher Pharmaceuticals Inc. CPH
Free
No email, no account, no signup.
General analysis — not personal advice.
Bull
Bear
Want to follow Cipher Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Exchange
TSX
Type
Biotech
Sector
Specialty Pharmaceuticals
Price & valuation
Last close
CAD 17.95
1 week
+6.1 %
3 months
-0.1 %
12 months
+20.1 %
From 52w high
-9.1 %
From 52w low
+36.5 %
We're already tracking Cipher Pharmaceuticals Inc. — here are the latest events we've registered
Recent News
- On July 6, 2026, Cipher Pharmaceuticals announced it signed a letter of intent with the pan-Canadian Pharmaceutical Alliance regarding public drug plan coverage for Epuris in Canada. On July 31, 2026, the company announced that it will release its second-quarter 2026 financial results on August 11, 2026.
What Firelda Watch includes for Cipher Pharmaceuticals Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — AI roundup of the week's news
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Cipher Pharmaceuticals Inc. will be delivered in the same format.
Want to follow Cipher Pharmaceuticals Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.